8-K: Onconetix Amends Forbearance Agreement with Veru, Extends Debt Maturity

Onconetix has amended its forbearance agreement with Veru, extending the maturity date of a $5 million note to June 30, 2025, and modifying payment terms on existing debt.

Summary

• Onconetix, Inc. has entered into an Amended and Restated Forbearance Agreement with Veru Inc., modifying the terms of a previous agreement related to a $20 million asset purchase.
• The agreement extends the due date for a $5 million note from September 30, 2024, to June 30, 2025.
• Interest at 10% per annum will accrue on the unpaid principal of both the April and September notes, starting April 20, 2024, and October 1, 2024, respectively.
• Monthly payments equal to 25% of certain cash receipts will be made towards the April note, starting October 20, 2024, and 20% of net proceeds from financing or asset sales will also be applied.
• If the total outstanding debt is repaid in cash by December 31, 2024, the principal balance of the September note will be reduced from $5 million to $3.5 million.
• Veru's Series A Preferred Stock will be converted to common stock after a reverse stock split and conversion of Series B Preferred Stock.
• Onconetix will reimburse Veru for up to $7,500 in legal fees related to the agreement.

Sentiment

Score: 4

Explanation: The document indicates financial challenges and debt restructuring, which is not a positive sign. However, the company has secured an extension on its debt, which is a positive. The overall sentiment is cautiously negative.

Positives

• The extension of the maturity date for the $5 million note provides Onconetix with additional time to manage its debt obligations.
• The potential reduction of the September note's principal balance to $3.5 million if repaid by December 31, 2024, offers a significant cost saving.
• The agreement allows for the possibility of paying the September note in common stock, providing flexibility in managing cash flow.
• The forbearance agreement prevents Veru from exercising its rights and remedies under the notes, providing stability for Onconetix.

Negatives

• The agreement includes a 10% per annum interest rate on the unpaid principal of both the April and September notes, increasing the cost of debt.
• The monthly payments of 25% of certain cash receipts and 20% of net proceeds from financing or asset sales could strain Onconetix's cash flow.
• The agreement includes cross-default provisions, meaning a default on one note triggers a default on all notes.
• The company has acknowledged a material event of default on the April 2024 Promissory Note due to failure to pay at maturity.

Risks

• Failure to meet the payment obligations under the forbearance agreement could lead to an event of default, allowing Veru to exercise its rights and remedies.
• The company's ability to generate sufficient cash flow to meet the required payments is uncertain.
• The company's reliance on financing or asset sales to make payments could be risky.
• The cross-default provisions increase the risk of a cascading default if any payment obligations are missed.

Future Outlook

The company is focused on meeting its payment obligations under the amended forbearance agreement and exploring options for repayment, including potential stock issuance. The company is also working towards the conversion of preferred stock to common stock.

Management Comments

• The company has agreed to make required payments during the April 2024 Forbearance Period.
• The company has agreed to certain amendments to the September Veru Note.
• The company has agreed to convert Veru's Series A Preferred Stock to common stock after a reverse stock split and conversion of Series B Preferred Stock.

Industry Context

This announcement reflects a common situation for biotech companies that are pre-revenue and reliant on financing. The need to restructure debt and extend payment terms is not uncommon in the industry, especially for companies that have made acquisitions and are working to commercialize their products.

Comparison to Industry Standards

• Many small biotech companies face similar challenges in managing debt and financing operations, often relying on a combination of debt and equity financing.
• The 10% interest rate on the notes is relatively high, reflecting the risk associated with lending to a pre-revenue company.
• The use of forbearance agreements and debt restructuring is a common practice in the biotech industry to manage financial obligations.
• The potential for debt to be converted into equity is also a common mechanism used by biotech companies to manage their balance sheets.

Stakeholder Impact

• Shareholders face potential dilution if the September note is paid in common stock.
• Creditors, specifically Veru, have extended the payment terms but are also receiving a higher interest rate and a share of future revenues.
• Employees may be impacted by the company's financial situation and the need to meet payment obligations.

Next Steps

• Onconetix needs to make the required payments under the amended forbearance agreement.
• The company needs to obtain stockholder approval for its reverse stock split proposal.
• The company needs to effectuate a reverse stock split of its outstanding shares of Common Stock and the conversion of all Series B Preferred Stock of the Company into shares of Common Stock.
• The company needs to convert Veru's Series A Preferred Stock into common stock.
• The company needs to monitor cash receipts and financing activities to ensure compliance with the payment terms.

Key Dates

Keywords

forbearance agreement, debt restructuring, promissory note, maturity extension, interest rate, cash receipts, financing, asset sales, preferred stock, common stock, default, Onconetix, Veru